Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Durvalumab	264
Overall Study	STARTED	Durvalumab Plus Tremelimumab	200
Overall Study	STARTED	Placebo	266
Overall Study	Safety Population	Durvalumab	262
Overall Study	Safety Population	Durvalumab Plus Tremelimumab	0
Overall Study	Safety Population	Placebo	265
Overall Study	COMPLETED	Durvalumab	0
Overall Study	COMPLETED	Durvalumab Plus Tremelimumab	0
Overall Study	COMPLETED	Placebo	0
Overall Study	NOT COMPLETED	Durvalumab	264
Overall Study	NOT COMPLETED	Durvalumab Plus Tremelimumab	200
Overall Study	NOT COMPLETED	Placebo	266

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03703297/flow